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In an effort to combat diseases and disorders that impede our health, comfort and
well-being, an abundance of prescription drugs have emerged in the past 60 years. Many
prescription drugs have remarkable efficacy for treating the primary symptoms of these
diseases and disorders; however, some drugs carry negative side effects that impose their
own adverse symptoms, albeit, often to a lesser degree than the primary symptoms. Thus,
one of the main objectives of the pharmaceutical industry is to innovate and develop
novel therapeutics, which remediate the primary symptoms of disease and lack
undesirable negative side effects. However, in order to develop effective novel
therapeutics, a comprehensive understanding of the underlying mechanisms of current
drugs is critical. The work within this thesis investigates the mechanisms of two
neuroactive drugs, which are commonly prescribed by physicians. Chapter I investigates
modafinil (Provigil®), which is therapeutic for sleep and psychiatric disorders, and drug
addiction therapy. Chapter II investigates atomoxetine (Strattera®), which is prescribed
for attention deficit hyperactivity disorder (ADHD) and possesses limited abuse potential,

in contrast to current ADHD medications, Adderall® and Ritalin®, which are addictive.
The effects of modafinil and atomoxetine on phasic dopamine signaling were
investigated. Phasic dopamine signaling has been identified critical for reward learning
and seeking, and is hypothesized to contribute to deficits in ADHD and drug addiction.
The results herein suggest that alterations in phasic dopamine signaling are involved in
the underlying mechanism of modafinil and atomoxetine action and may ultimately
contribute to their therapeutic efficacy.

KEYWORDS: Dopamine, Fast-scan cyclic voltammetry, Modafinil, Atomoxetine,
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CHAPTER I
MODAFINIL ACTIVATES PHASIC DOPAMINE SIGNALING IN THE DORSAL
AND VENTRAL STRIATUM OF THE RAT

1

ABSTRACT
Modafinil (MOD) is a psychomotor stimulant exhibiting therapeutic efficacy for
treating sleep, psychiatric disorders, and drug addiction. However, its mechanism of
action is incompletely understood. Compared to other psychomotor stimulants inhibiting
dopamine (DA) uptake, MOD weakly interacts with the dopamine transporter (DAT) and
elicits lower elevations in dialysate DA in the striatum, suggesting additional MOD
targets. However, the ability of MOD to induce wakefulness is abolished in DATknockout mice, suggesting that DAT is necessary for MOD action. Another
pharmacologic target for psychomotor stimulants, but one not established for MOD, is
the activation of phasic DA signaling. This mode of DA neuronal communication is
implicated in reward learning and consists of burst firing of DA neurons generating rapid
changes in extracellular DA termed transients. Here we investigated the effects of MOD
on phasic DA signaling in the striatum of urethane-anesthetized rats with fast-scan cyclic
voltammetry. We found that MOD (30-300 mg/kg i.p.) robustly increased the amplitude
of electrically evoked phasic-like DA signals in a time- and dose-dependent fashion, with
greater enhancement in the dorsal than ventral striatum. Analysis of these evoked signals
to assess presynaptic mechanisms demonstrated that MOD also increases DA release and
decreases DA uptake also in a time- and dose-dependent manner. Principal component
regression of non-electrically evoked recordings revealed negligible changes in basal DA
levels with high-dose MOD (300 mg/kg i.p.). Lastly, in the presence of the D2 DA
antagonist, raclopride, to relieve anesthesia blunting of burst firing by DA neurons, lowdose MOD (30 mg/kg i.p.) robustly elicited DA transients in the dorsal and ventral
striatum. Taken together, these results suggest that activation of phasic DA signaling is
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an important mechanism underlying the clinical efficacy of MOD. Figure 1 summarizes
our findings.
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Introduction
Modafinil (MOD; Provigil®) is a psychomotor stimulant exhibiting therapeutic
efficacy for treating a variety of neuropathologies, including sleep-related disorders such
as narcolepsy (Wise et al., 2007), obstructive sleep apnea syndrome (Pack et al., 2001),
and shift-work sleep disorder (Czeisler et al., 2005), psychiatric disorders such as
attention deficit hyperactivity disorder (ADHD) (Swanson et al., 2006) and schizophrenia
(Ballon and Feifel, 2006), and drug addiction (Anderson et al., 2009; Shearer et al., 2009;
Anderson et al., 2012). Similar to other psychomotor stimulants used therapeutically,
such as amphetamine (Adderall®) and methylphenidate (Ritalin®), MOD enhances
locomotor activity (Kuczenski et al., 1991; Edgar and Seidel, 1997; Kuczenski and Segal,
2001) and wakefulness (Wisor et al., 2001; Ishizuka et al., 2008), and exhibits cognitive
enhancing properties (Barch and Carter, 2005; Kumar, 2008; Repantis et al., 2010).
Indeed, a recent meta-analysis study has concluded that MOD can be used safely as a
cognitive enhancer in normal, healthy subjects (Battleday and Brem, 2015). However,
unlike other therapeutic psychomotor stimulants, MOD exhibits limited potential for
abuse (Deroche-Gamonet et al., 2002). This attractive property has generated
considerable interest in establishing the neuropharmacologic mechanism of MOD.
Although MOD has been found to modulate various neurotransmitters in the
brain, including histamine, hypocretin (orexin), GABA, glutamate, norepinephrine, and
serotonin, its effects on dopamine (DA) have received the greatest attention (Tanganelli
et al., 1992; Ferraro et al., 1997a; Ferraro et al., 1997b; Chemelli et al., 1999; de Saint et
al., 2001; Ishizuka et al., 2003). This atypical psychomotor stimulant appears to
preferentially interact with the dopamine transporter (DAT), compared to the transporters
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for norepinephrine and serotonin, and to show little affinity for receptors for the
monoamines and other neurotransmitters (Mignot et al., 1994; Madras et al., 2006;
Zolkowska et al., 2009). However, whether MOD acts directly through DAT is
controversial. On one hand, MOD exhibits weak affinity for DAT (Mignot et al., 1994;
Madras et al., 2006; Zolkowska et al., 2009) and elicits only relatively modest increases
in striatal dialysate DA (Ferraro et al., 1997b; Loland et al., 2012). On the other hand,
MOD’s effects appear to rely on DAT, as MOD-induced wakefulness is abolished in
DAT-knockout mice (Wisor et al., 2001).
Based on work investigating actions of other DAT-inhibiting psychomotor
stimulants, another potential target for MOD is phasic DA signaling. DA neurons signal
in two distinct modes: tonic and phasic (Grace and Bunney, 1984a; Grace and Bunney,
1984b). Slow, irregular firing of DA neurons generates a basal extracellular level of DA
called tone during tonic DA signaling, whereas burst firing of DA neurons generates
rapid increases in extracellular DA called transients during phasic DA signaling (Grace
and Bunney, 1984a; Sombers et al., 2009). Phasic DA signaling is involved in reward
learning (Schultz et al., 1997; Day et al., 2007) and seeking (Phillips et al., 2003b), and
alterations in phasic DA signaling are hypothesized to contribute to ADHD (Tripp and
Wickens, 2008) and drug addiction (Covey et al., 2014). Several DAT-inhibitor
psychomotor stimulants have been shown to activate phasic DA signaling by increasing
burst firing of DA neurons (Shi et al., 2000; Shi et al., 2004; Koulchitsky et al., 2012) and
the frequency of DA transients in the striatum (Venton and Wightman, 2007; Covey et
al., 2013; Daberkow et al., 2013). DAT-inhibiting psychostimulants have also been
shown to act presynaptically to enhance DA release in addition to inhibiting DA uptake
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(Wu et al., 2001a; Venton et al., 2006; Chadchankar and Yavich, 2012). Whether MOD
acts similarly to activate phasic DA signaling has not been examined.
Here we use fast-scan cyclic voltammetry (FSCV) at a carbon-fiber
microelectrode (CFM) to investigate the effects of MOD on phasic DA signaling in
urethane-anesthetized rats. The effects of MOD were examined in the dorsal and ventral
striatum across a wide behaviorally relevant range of doses (30 - 300 mg/kg i.p.) (Edgar
and Seidel, 1997; Beracochea et al., 2001; Ward et al., 2004). Two measures of phasic
DA signaling were assessed: the amplitude of electrically evoked phasic-like DA signals
and DA transients elicited in the presence the D2 DA antagonist, raclopride, to overcome
anesthesia blunting of burst firing by DA neurons (Shi et al., 2000; Shi et al., 2004;
Venton and Wightman, 2007). In addition, the effects of MOD on the presynaptic
mechanisms of DA release and uptake (Wu et al., 2001b) and on tonic DA levels as
analyzed using principle component regression (PCR) (Keithley et al., 2009) were also
determined. Taken together, our results suggest that activation of phasic DA signaling is
a novel mechanism contributing to the therapeutic efficacy of MOD.
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Materials and Methods
Animals. Male Sprague-Dawley rats (300-400 g) were purchased from Harlan
(Indianapolis, IN, USA) and housed in a temperature-controlled vivarium on a diurnal
light cycle (12h light/dark) with food and water provided ad libitum. Animal care
conformed to the NIH Guide for the Care and Use of Laboratory Animals and
experimental procedures were approved by the Institutional Animal Use and Care
Committees at Illinois State University.
Surgery. Rats were anesthetized with urethane (1.6 g/kg, i.p.) and immobilized in a
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). Holes for reference,
stimulating, and two CFMs were drilled. All coordinates, anteroposterior (AP),
mediolateral (ML) and dorsoventral (DV), are given in mm and are referenced to bregma
(Paxinos and Watson, 1986). The stimulating electrode targeted the medial forebrain
bundle (MFB; -4.6 AP, +1.3 ML, -7.5 DV). CFMs targeted the dorsal (+1.2 AP, +3.0
ML, -4.5 DV) and ventral (+1.2 AP, +1.5 ML, -6.5 DV) striatum. The Ag/AgCl reference
electrode was placed in the contralateral superficial cortex.
Experimental Design. DA was recorded in sequential 5-minute epochs and for most
recordings, FSCV was performed simultaneously at separate CFMs implanted in the
dorsal and ventral striatum of a single animal. In the first experimental design, four predrug and 30 post-drug epochs were collected, and electrical stimulation of the MFB was
applied 5 seconds into each epoch. The effects of vehicle (2-hydroxypropyl)-βcyclodextrin (vehicle) or MOD (30, 60, 100 or 300 mg/kg) were examined on electrically
evoked DA signals for the entire duration of DA measurements (15 min pre-drug and 160
min post-drug. The effects of vehicle or MOD across the same dose range as above on
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DA release and uptake were examined pre-drug and at 30 and 60 min post-drug. The
effects of vehicle or high-dose MOD (300 mg/kg) on changes in basal DA levels were
examined pre-drug for 40 min post-drug. In the second experimental design, electrical
stimulation was applied pre-drug and every 30 min post-drug to assess the veracity of the
CFM. After pre-drug recordings, raclopride (2 mg/kg) was co-administered with lowdose MOD (30 mg/kg) and DA transients were analyzed during 5-min epochs pre-drug
and post-drug at 15, 30, 60 and 120 min. All vehicle and drugs were administered
intraperitoneally (i.p.) in a total volume of 2 ml. n = 4-7 each in the dorsal and ventral
striatum.
Electrochemistry. DA measurements were recorded with FSCV at a CFM by
applying a triangular waveform (-0.4 to +1.3V and back) at a rate of 400V/s every 100
ms. CFMs were fabricated by aspirating a single carbon fiber (r=3.55 µm; HexTow AS4,
HexCel Corp., Stamford, CT, USA) into a borosilicate capillary tube (1.2mm o.d.; Sutter
Instrument, Novato, CA, USA) and pulling to a taper using a micropipette puller
(Narishige, Tokyo, Japan). The carbon fiber was then cut to ~100 µm distal to the glass
seal. FSCV was performed by a Universal Electrochemistry Instrument (UEI;
Department of Chemistry Electronic Shop, University of North Carolina, Chapel Hill,
NC, USA) and commercially available software (ESA Bioscience, Chelmsford, MA,
USA). Current recorded at peak oxidative potential for DA (~+0.6 V) was converted to
DA concentration based on post-calibration of the CFM using flow-injection analysis in a
modified TRIS buffer (Kume-Kick and Rice, 1998; Wu et al., 2001b; Phillips et al.,
2003a). DA was initially identified from the background subtracted voltammogram
(Michael et al., 1998; Heien et al., 2004).

8

Measurements with Electrical Stimulation. Electrical stimulation was computer
generated and passed through an optical isolator and constant-current generator
(Neurolog NL800; Digitimer Limited, Letchworth Garden City, UK). Biphasic
stimulation pulses were applied to a twisted bipolar electrode (Plastics One, Roanoke,
VA, USA), with tips separated ~1 mm. Stimulus parameters were ±300 μA intensity and
4 ms biphasic pulses (2 ms each phase), trains were applied at a frequency of 60 Hz for
0.4 s.
Analysis of Dopamine Release and Uptake. Electrically evoked phasic-like DA
signals were analyzed to determine maximal amplitude ([DA]max) and parameters for
presynaptic DA release and uptake according to (Wightman et al., 1988; Wu et al.,
2001b):
[1]

d[DA]/dt = [DA]p*f - k[DA]

where [DA]p is the concentration of DA elicited per stimulus pulse used to index DA
release, k is the first-order rate constant for DA uptake, and f is the frequency of electrical
stimulation. [DA]p and k were determined by fitting data to equation 1 using a nonlinear
regression with a simplex-minimization algorithm (Wu et al., 2001b). Temporal
distortion in measured DA responses was accounted for using a diffusion gap model, with
the width held constant for each CFM across pre- and post-drug measurements (Wu et al.,
2001b).
Analysis of Basal Dopamine Levels and Dopamine Transients. Changes in nonelectrically evoked DA levels were assessed using PCR to resolve DA, pH, and
background drift from FSCV recordings (Hermans et al., 2008; Keithley et al., 2009). In
select files, PCR additionally resolved a repetitive background noise component. PCR
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analysis was accepted if any current in the recordings not accounted for by the retained
principal components of the training sets, or residual (Q), was less than the 95%
confidence threshold (Qα). Epochs where Q exceeded Qα were not used for analysis.
Changes in baseline DA levels (Δ[DA]) per 5 min-epoch were determined by averaging
all data points post-stimulation of PCR-resolved traces. Data are presented as Δ[DA]
within each five-minute epoch and not as a contiguous concatenation to avoid resetting Q
with a new background subtraction at the start of each epoch. DA transients were
identified in PCR-resolved traces as peaks greater than 5-times the root-mean-squarenoise using peak-finding software (MINI ANALYSIS; Synaptosoft, Decatur, GA, USA).
Statistical Analysis. Where appropriate, data are expressed as the mean±SEM.
Unless noted below, statistical analyses were performed with SAS version 9.3 (SAS
Institute). Time courses for [DA]max, [DA]p, and k were analyzed using a three-way
ANOVA with repeated measures with time, drug dose, and striatal region as factors. Path
analysis was conducted to assess the direct and indirect influences of [DA]p and k on
dose-dependent effects of MOD on [DA]max. Alternative path analyses were conducted to
compare Akaike Information Criteria (AIC) of reduced models to those of the complete
model. A two-way ANOVA with repeated measures assessed differences in DA transient
frequency with time and dose as factors. Correlations were performed with Sigma Plot
12.0 (Systat Software Inc., San Jose, CA, USA). Significance was set at p < 0.05.
Drugs. Urethane, (2-hydroxypropyl)-β-cyclodextrin and raclopride were purchased
from Sigma (St. Louis, MO, USA). MOD was provided by Research Triangle InstituteNational Institute on Drug Abuse, Raleigh, NC. Urethane and raclopride were dissolved
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in 150 mM NaCl prior to injection. MOD was dissolved in a mixture of 50% (2hydroxypropyl)-β-cyclodextrin and nanopure w/v.

11

Results
Modafinil Robustly Increases the Amplitude of Electrically Evoked Phasic-Like
Dopamine Signals. Figure 2 shows representative effects of MOD on electrically evoked
phasic-like DA signals collected in the dorsal (Fig. 2A) and ventral (Fig. 2B) striatum. In
the top of each panel, electrical stimulation of MFB increased [DA] as measured by
FSCV at a CFM. Pseudo-color plots below, which serially display all voltammograms
collected during the recording, and individual voltammograms (inset) identify DA as the
primary analyte recorded based on the electrochemical profile. MOD (100 mg/kg)
increased [DA]max in both the dorsal and ventral striatum 60 minutes post-drug
administration.
Figure 3 shows averaged time courses of MOD effects on [DA]max expressed as a
percent change from pre-drug in the dorsal (Fig. 3A) and ventral (Fig. 3B) striatum. All
four doses, 30, 60, 100, 300 mg/kg MOD, appeared to elevate [DA]max compared to
vehicle control for more than 2.5 hours post-drug administration. Consistent with
representative recordings shown in figure 2, averaged MOD appeared to elevate [DA]max
to a greater extent in the dorsal than in the ventral striatum. A three-way repeated
measures ANOVA revealed significant effects of time (F33,1419 = 30.83, p = <0.0001),
dose (F4,43 = 15.47, p = <0.0001), and region (F1,43 = 5.85, p = <0.0198); thus, MOD
increased [DA]max in a time- and dose-dependent manner with a greater effect in the
dorsal striatum. There were also significant time-by-dose (F132, 1419 = 9.04, p =
<0.0001) and time-by-region (F132, 1419 = 4.17, p = 0.0207) interactions but no regionby-dose interaction (F4, 43 = 0.70, p = <0.5970).
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Modafinil Increases Dopamine Release and Decreases Dopamine Uptake. MODinduced increases in [DA]max could be mediated by enhanced DA release and/or inhibited
neuronal DA uptake. To initially assess whether MOD decreased DA uptake, electricallyevoked decay curves were overlaid at the same concentration (Fig. 4 inset) and the slopes
were visually inspected between pre- and post-drug traces. The downward slope of the
evoked trace is thought to be due to DA uptake and not DA release (Wu et al., 2001b).
Thus, the flatter post-drug traces after MOD indicates slower DA clearance from the
extracellular space (Fig. 4). This qualitative approach suggests that MOD appears to
decrease DA uptake, suggesting that the increase in [DA]max may be DA uptake
inhibition, at least in part. However, MOD-induced increases in DA release may also play
a role, because the upward slope of the evoked trace is due to the balance of DA release
and uptake (Wu et al., 2001b).
To quantitatively resolve MOD’s effect on DA release and uptake on [DA]max,
electrically evoked responses were fit to Eq. 1. Figure 5 shows [DA]max (left), DA release
as indexed by [DA]p (middle), and DA uptake as indexed by k (right) for the dorsal (Fig.
5A) and ventral (Fig. 5B) striatum. Three time points were assessed: pre-drug, 30 min,
and 60 min. Three-way repeated measures ANOVA was used for statistical analysis for
each parameter. Statistical analysis of [DA]max revealed significant effects of time (F2, 88
= 60.28, p = <0.0001), dose (F4, 44 = 3.47, p = 0.0151), and time-by-dose interaction
(F8, 88 = 15.59, p = <0.0001) but no significant effect of region (F1, 44 = 2.79, p =
0.1022). The nonsignificant regional effect in this analysis was most likely attributed to
the reduced number of time points examined at maximal drug (> 60 min) as compared to
the complete time course in figure 3. Analysis of [DA]p revealed significant effects of
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time (F2, 88 = 37.48, p = <0.0001), dose (F4, 44 = 3.30, p = 0.0189), and time-by-dose
interaction (F8, 88 = 9.23, p = <0.0001) but no significant effect of region (F1, 44 = 0.18,
p = 0.6774). Finally, analysis of k revealed significant effects of time (F2, 88 = 56.82, p =
<0.0001) and region (F1, 44 = 7.72, p = 0.008), as well as a time-by-dose interaction (F8,
88 = 3.82, p = 0.0023). Taken together, these results demonstrate that MOD increases DA
release and decreases DA uptake in a time-dependent fashion.
We next used path analysis to evaluate the respective contribution of increased
DA release and decreased DA uptake to the dose-dependent effects of MOD on [DA]max
in order to gain more insight into whether one of these presynaptic mechanisms is
preferentially targeted. Path analysis is a statistical technique that tests effects of multiple
independent variables on a dependent variable, much like multiple regression; however,
path analysis allows for the possibility that variables can be both dependent and
independent (i.e., variables can be both affected by dose and affect other variables). The
output of path analysis, path coefficients, are standardized regression coefficients and
indicate the strength and direction (i.e., positive or negative) of the relationship between
the variables.
Figure 6 shows the complete model for path analysis, with arrows demarcating
direct relationships between variables and the path coefficient given above each arrow.
Path analysis of the complete model suggests that MOD dose exerts an almost equal, but
opposite, direct effect on DA release (+0.6359) and uptake (-0.6571); thus, increasing the
dose of MOD increases DA release and decreases DA uptake to a similar magnitude.
However, DA release exerted a greater effect on [DA]max as compared to DA uptake,
+0.9192 and -0.1423 respectively, suggesting that DA release was preferentially targeted
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by MOD to increase [DA]max. Based on 95% confidence intervals, the effect of MOD
dose on DA release (95% confidence interval, 0.48-0.80) and uptake (95% confidence
interval, 0.50-0.81) was not significantly different but that the effect of DA release (95%
confidence interval, 0.88-0.96) on [DA]max was significantly greater than that of DA
uptake (95% confidence interval, 0.09-0.20). Lastly, path analyses for alternative models
(i.e., omitting either DA uptake or release) were conducted, and AIC values between
were compared to determine which model was most appropriate. Omitting DA uptake or
DA release resulted in increased AIC, (44 and 196 respectively), as compared to the
original model (19), which included both parameters, suggesting that both DA release
and uptake together best explain the MOD dose effects on [DA]max as compared to
individually. Additionally, the larger AIC calculated after omission of DA release, as
compared to DA uptake, suggests that when DA release is omitted the model has a
weaker fit, which is consistent with path coefficients derived for the complete model.
Modafinil Has Negligible Effects on Basal Dopamine Levels. MOD effects on
basal DA levels were assessed by applying a chemometrics analysis technique termed
PCR (Hermans et al., 2008; Keithley et al., 2009) to the non-electrically evoked portion
of the raw FSCV recording. Figure 7A shows representative FSCV and PCR recordings
for pre-drug and 60 minutes post-300 mg/kg MOD, the highest dose tested. The raw
FSCV recording (top; black trace) shows a steady increase in current for both pre- and
post-drug conditions (left and right, respectively). However, the current cannot be
attributed solely to DA as the color plot below shows additional electrochemical changes
not attributed to DA. Furthermore, the voltammogram (inset) contains other analytes
(blue) that would mask changes in DA (black) if present. PCR resolves DA from these
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interferents and these representative traces resolved by PCR (red) suggest negligible
changes in basal DA levels with MOD.
To assess MOD-induced changes in basal DA levels within individual 5 minepochs (Δ[DA]), all data points in PCR resolved DA files after the electrically evoked
response returned to baseline were averaged pre-drug and for the first 40 min of drug
response. The time period was selected to examine the initial effects of MOD on basal
extracellular DA corresponding to the initial robust increase in electrical evoked phasiclike DA signals (Fig. 3). Time 0 min was excluded because of noise introduced during
drug administration. MOD had negligible effects on Δ[DA] (Fig. 7B) in either the dorsal
(top) or ventral (bottom) striatum. The three-way repeated measures ANOVA revealed no
significant effect of time (F10, 90 = 1.80, p = 0.1764), dose (F1, 9 = 0.11, p = 0.7433), or
region (F1, 9 = 0.47, p = 0.5118), indicating that there was no significant effect of MOD
on basal DA levels. Additionally, there were no significant interactions.
To verify PCR selectivity for the DA component, a linear regression was
performed between [DA]max from raw FSCV recordings ([DA]FSCV) and PCR-resolved
data ([DA]PCR). The current attributed to the electrically-evoked response measured in the
FSCV trace over short time scales has previously been described to be primarily DA
(Wightman et al., 1986). Thus, the tight association of data points to the trend line and
significant correlation between [DA]FSCV and [DA]PCR in both the dorsal (Fig. 7C left; r =
0.8901, p < 0.0001) and ventral (Fig. 7C right; r = 0.9639, p < 0.0001) striatum suggests
that PCR accurately resolved DA from the mixed analyte signal.
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Modafinil Activates Dopamine Transients. Under anesthesia, DAT-inhibiting
psychomotor stimulants exert an inhibitory effect on DA neuron firing (Shi et al., 2000;
Shi et al., 2004), yet an excitatory action in freely behaving rats (Koulchitsky et al.,
2012). Co-administration of a DA D2 receptor antagonist alleviates the blunting effects
produced under anesthesia, allowing these DAT-inhibitors to elicit burst firing of DA
neurons (Shi et al., 2000; Shi et al., 2004) and DA transients (Venton and Wightman,
2007) under these conditions. Similar to other DAT-inhibiting psychomotor stimulants,
co-administration of MOD (30 mg/kg) and raclopride (2 mg/kg), a DA D2 receptor
antagonist, induced DA transients in both the dorsal (Fig. 8A left) and ventral (Fig. 8A
right) striatum. Asterisks demark transients on the FSCV current trace taken at the peak
DA oxidation potential. Transients were confirmed to be DA by the electrochemical
profile in the pseudo-color plot and comparison of the individual transient
voltammograms (inset, red) to electrically evoked DA voltammograms (inset, black).
Prior to assessing transient frequency at select time points, DA in the FSCV traces was
resolved with PCR. As shown in figure 8B, there were no transients pre-drug, which
sharply contrasts the robust increase in transient frequency 15 minutes post-drug
administration and after. A two-way repeated measures ANOVA revealed a significant
effect of time on transient frequency (F3, 27 = 11.85, p = <0.0001). However, there were
no significant effects of region (F1, 9 = 0.18, p = 0.6835) or a significant time-by-region
interaction (F3, 27 = 1.72, p = 0.1932).
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Discussion
Here we demonstrate using FSCV at a CFM in the anesthetized rat that MOD
activates phasic DA signaling in both the dorsal and ventral striatum without altering
basal DA levels. The activation of phasic DA signaling was indicated by an increase in
the amplitude of electrically evoked phasic-like DA signals and the frequency of DA
transients assessed in the presence of the DA D2 antagonist, raclopride. MOD
additionally acted presynaptically to increase DA release and decrease DA uptake,
although the former action contributed to a greater extent to the increase in evoked DA
signal. Taken together, the results suggest that activation of phasic DA signaling is a
novel mechanism of MOD that may contribute to its therapeutic efficacy.
Modafinil Effects on Basal Dopamine Levels. In the current study, PCR revealed
no significant changes in basal DA levels in either the dorsal or ventral striatum after
administration of the highest dose of MOD tested (300 mg/kg). In contrast, microdialysis
studies report a ~3-fold elevation in striatal DA levels at the same dose (Loland et al.,
2012). These discrepancies may be attributed to differences in analytical techniques.
Traditionally, microdialysis has been used to measure basal DA levels due to its high
chemical selectivity and sensitive detection limits (Watson et al., 2006), whereas FSCV is
better suited for capturing rapid changes in DA levels, such as DA transients, based on
fast temporal resolution and smaller probe size (Roberts et al., 2013). Due to recent
technical improvements in FSCV, along with advances in data analysis using PCR,
changes in basal DA levels are now beginning to be assessed with this technique
(Keithley et al., 2009). However, discrepancies between FSCV and microdialysis in
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measuring basal DA levels are not well understood and as a result, the definitive
determination of whether MOD acts on basal DA levels requires further study.
Modafinil Effects on Phasic Dopamine Signaling. Naturally occurring DA
transients can be mimicked in amplitude and dynamics using electrical stimulation with
judicious selection of stimulus parameters (Robinson et al., 2001). The stimulus
parameters used here are reinforcing in the paradigm of intracranial self-stimulation
(Garris et al., 1999; Cheer et al., 2005) and elicit DA signals whose amplitude falls within
the range of these DA transients, albeit at the higher end (Robinson and Wightman,
2007). DAT-inhibiting psychomotor stimulants, such as cocaine and amphetamine, have
also been shown to robustly increase the amplitude of DA signals evoked by similar
stimulus parameters (Venton et al., 2006; Oleson et al., 2009; Ramsson et al., 2011;
Covey et al., 2013; Avelar et al., 2013). This increase in the electrically evoked DA
signal is thought to be relevant to drug action on phasic DA signaling, because both
cocaine and amphetamine also robustly activate DA transients in awake, freely behaving
animals (Stuber et al., 2005; Aragona et al., 2008; Daberkow et al., 2013). Whether MOD
also elicits DA transients in awake, freely behaving animals as do cocaine and
amphetamine remains to be determined. However, we also showed that MOD elicits DA
transients in the presence of raclopride, similar to cocaine (Park et al., 2010), further
suggesting that the activation of phasic DA signaling we observed for MOD in
anesthetized animals, as indexed by electrically evoked phasic-like DA signals and DA
transients measured in the presence of a DA D2 antagonist, is indicative of drug action in
awake, freely behaving animals.
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Similar to other DAT-inhibiting psychomotor stimulants such as cocaine,
amphetamine, and methylphenidate (Venton et al., 2006; Ramsson et al., 2011;
Chadchankar et al., 2012; Covey et al., 2013; Avelar et al., 2013; Daberkow et al., 2013),
we show that MOD increases DA release and decreases DA uptake. Thus, our results are
consistent with the notion that DAT-inhibiting psychomotor stimulants share a common
action of altering both presynaptic mechanisms (Covey et al., 2014). Because the upward
slope of the electrically evoked DA signal is determined by the balance of DA release
and uptake (Wightman et al., 1988), both presynaptic mechanisms could in theory
mediate the increase in amplitude of the electrically evoked phasic-like signaling elicited
by DAT-inhibiting psychomotor stimulants. However, while indirect evidence suggests
that the increase in DA release is more responsible for the increase in signal amplitude
compared to the decrease in DA uptake (Venton et al., 2006; Avelar et al., 2013; Covey
et al., 2013; Daberkow et al., 2013), this hypothesis has never been directly tested as we
do here. Indeed, our results using path analysis suggest that MOD-induced increases in
[DA]max are best explained by the enhancement of DA release, not the inhibition of DA
uptake. This result, if substantiated, may inform the regulation of DA transients by DATinhibiting psychomotor stimulants. For example, while it is thought that an increase in
burst firing of DA neurons drives the increase in transient frequency (vide infra) and
inhibited DA uptake drives the increase in transient duration, the mechanism of the
increase in transient amplitude is debated (Covey et al., 2013). Assuming electrically
evoked phasic-liked DA signals appropriately model DA transients, our results suggest
that enhanced DA release, not inhibited DA uptake, is responsible for the increase in
transient frequency with DAT-inhibiting psychomotor stimulants. However, caution is
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urged, because there are other kinetic models available for analyzing DA release and
uptake from the electrically evoked DA signal (Walters et al., 2014; Harun et al., 2015)
besides the diffusion-gap model that we employed, and these models should also be
applied to address the relative contribution of DA release and DA uptake to [DA]max.
Our findings show that MOD, at the lowest dose tested (30 mg/kg), elicited DA
transients in both the dorsal and ventral striatum. Interestingly, the frequency of DA
transient elicited was similar to that for a high affinity DAT-inhibitor, nomifensine, under
similar conditions (Venton and Wightman, 2007), which suggests that the MOD-induced
activation of DA transients is robust. Because co-administration of a DA D2 antagonist is
a confound, it is difficult to compare these rates of transient frequency activation with
those observed with DAT-inhibiting psychomotor stimulants in awake, freely behaving
animals. The ability of MOD to increase the frequency of DA transients in the dorsal and
ventral striatum would appear to be due to activation of burst firing of DA neurons.
Anesthetics blunt this burst firing (Kelland et al., 1990) and under these conditions, DATinhibiting psychomotor stimulants inhibit the firing rate of DA neurons (Shi et al., 2000;
Shi et al., 2004). However, administration of a DA D2 antagonist relieves the blunting
effects of anesthesia and reveals a drug-induced activation of burst firing of DA neurons
similar to that observed in awake, freely behaving animals (Shi et al., 2000; Shi et al.,
2004; Koulchitsky et al., 2012). We therefore hypothesize that MOD similarly increases
burst firing of DA neurons in awake, freely behaving animal, although this hypothesis
remains to be tested. Taken together, our results obtained in the urethane-anesthetized rat
suggest the MOD mechanism of eliciting burst firing of DA neurons, which generates
DA transients in the dorsal and ventral striatum, and increasing the amplitude and
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duration of these DA transients by the presynaptic actions of enhancing DA release and
inhibiting DA uptake, respectively. Our results, furthermore, do not implicate an action of
MOD on tonic DA signaling.
Addictive Nature of Psychomotor Stimulants. A long-held view in addiction
research is that, despite diverse cellular actions, all drugs of abuse increase brain
extracellular levels of DA, with a preferential action in the ventral compared to the dorsal
striatum (Di and Imperato, 1988). More recent work has refined this view by
hypothesizing that all drugs of abuse hyperactive phasic DA signaling (Cheer et al., 2004;
Cheer et al., 2007; Daberkow et al., 2013; Vander Weele et al., 2014), leading to the
hijacking of reward circuits and aberrant reward learning (Hyman et al., 2006). While
cocaine and amphetamine conform to this general hypothesis (Venton and Wightman,
2007; Covey et al., 2013; Daberkow et al., 2013), other mechanisms have been
considered to explain differences in abuse potential for DAT-inhibiting psychomotor
stimulants including, affinity for DAT (Ritz et al., 1987), speed of drug action in the
brain (Yorgason et al., 2011), and actions on DAT mimicking G protein-coupled
receptors, as in the so-called “transceptor” (Schmitt et al., 2013). We also show here that
in contrast to the addictive DAT-inhibiting psychomotor stimulants, cocaine and
amphetamine, which elicit preferential increases in phasic DA signaling in the ventral
compared to the dorsal striatum (Ritz et al., 1987; Wu et al., 2001a; Ramsson et al., 2011;
Covey et al., 2013), MOD either preferentially increased electrically evoked phasic-like
DA signals in the dorsal compared to the ventral striatum or shows no striatal sub-region
preference for activating DA transients. Consistent with this effect, nomifensine, another
DAT-inhibiting psychomotor stimulant with limited abuse potential (Tella et al., 1997),
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showed a similar preference for the dorsal striatum in increasing electrically evoked
phasic-like DA signals (Wu et al., 2001a). Whether other DAT-inhibiting psychomotor
stimulants with limited abuse potential show a similar preference for activating phasic
DA signaling in the dorsal compared to the ventral striatum should be further pursued.
Clinical Implications of Modafinil. Phasic DA signaling is critical in reward
seeking and learning (Schultz et al., 1997; Adamantidis et al., 2011), and reinforcement
deficits in ADHD patients are thought to arise from alterations in phasic DA signaling
(Tripp and Wickens, 2008). As MOD has been shown to remediate cognitive deficits in
ADHD (Swanson et al., 2006) and enhance cognition in non-ADHD patients (Muller et
al., 2013), it is interesting to speculate that MOD’s ability to activate phasic DA signaling
may contribute to its clinical efficacy. Additionally, phasic DA signaling has been linked
to cocaine self-administration (Willuhn et al., 2014), while MOD reduces cocaine and
methamphetamine administration in addicts (Anderson et al., 2009; Shearer et al., 2009).
Long-access cocaine self-administration also diminishes phasic DA signaling in the
striatum, but treatment with L-DOPA can restore phasic DA signaling and concomitantly,
cocaine self-administration decreases (Willuhn et al., 2014). Thus, it is interesting to
speculate that perhaps MOD’s ability to activate phasic DA signaling may restore drugdepressed phasic DA signaling, similarly to L-DOPA, and ultimately aid in the treatment
of drug addiction.
In addition to cognitive enhancement and drug addiction therapy, MOD is a wellestablished wake promoting agent. The mechanism of narcoleptic therapeutics is
incompletely understood, and MOD’s mechanism of treating narcolepsy is unknown.
More recent evidence suggests a role for DA in sleep-wakefulness (Wisor et al., 2001;
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Dahan et al., 2007), in addition to the well-established roles of serotonin, norepinephrine,
and acetylcholine (Pace-Schott and Hobson, 2002). Burst-firing of DA neurons also
changes between wake and paradoxical sleep states (Dahan et al., 2007). As burst firing
of DA neurons generates DA transients, it is interesting to speculate that MOD’s ability
to activate phasic DA signaling may be involved in promoting wakefulness.
Conclusion. Our results suggest that MOD’s therapeutic efficacy may be due, at
least in part, to its ability to activate phasic DA signaling. Further study in awake, freely
behaving animals should be pursued to substantiate this hypothesis based on evidence
described herein and collected in anesthetized animals.

24

REFERENCES
Adamantidis AR, Tsai HC, Boutrel B, Zhang F, Stuber GD, Budygin EA, Tourino C,
Bonci A, Deisseroth K, de LL (Optogenetic interrogation of dopaminergic
modulation of the multiple phases of reward-seeking behavior. J Neurosci
31:10829-10835.2011).
Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N,
Beresford T, Campbell J, Haning W, Mawhinney J, McCann M, Rawson R, Stock
C, Weis D, Yu E, Elkashef AM (Modafinil for the treatment of methamphetamine
dependence. Drug Alcohol Depend 120:135-141.2012).
Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R,
Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E,
Urschel HC, III, Elkashef AM (Modafinil for the treatment of cocaine
dependence. Drug Alcohol Depend 104:133-139.2009).
Aragona BJ, Cleaveland NA, Stuber GD, Day JJ, Carelli RM, Wightman RM
(Preferential enhancement of dopamine transmission within the nucleus
accumbens shell by cocaine is attributable to a direct increase in phasic dopamine
release events. J Neurosci 28:8821-8831.2008).
Avelar AJ, Juliano SA, Garris PA (Amphetamine augments vesicular dopamine release in
the dorsal and ventral striatum through different mechanisms. J Neurochem
125:373-385.2013).
Ballon JS, Feifel D (A systematic review of modafinil: Potential clinical uses and
mechanisms of action. J Clin Psychiatry 67:554-566.2006).
Barch DM, Carter CS (Amphetamine improves cognitive function in medicated
individuals with schizophrenia and in healthy volunteers. Schizophr Res 77:4358.2005).
Battleday RM, Brem AK (Modafinil for cognitive neuroenhancement in healthy nonsleep-deprived subjects: A systematic review. Eur Neuropsychopharmacol.2015).
Beracochea D, Cagnard B, Celerier A, le MJ, Peres M, Pierard C (First evidence of a
delay-dependent working memory-enhancing effect of modafinil in mice.
Neuroreport 12:375-378.2001).
Chadchankar H, Ihalainen J, Tanila H, Yavich L (Methylphenidate modifies overflow
and presynaptic compartmentalization of dopamine via an alpha-synucleindependent mechanism. J Pharmacol Exp Ther 341:484-492.2012).

25

Chadchankar H, Yavich L (Characterization of a 32mum diameter carbon fiber electrode
for in vivo fast-scan cyclic voltammetry. J Neurosci Methods 211:218-226.2012).
Cheer JF, Heien ML, Garris PA, Carelli RM, Wightman RM (Simultaneous
electrochemical and single-unit recordings in the nucleus accumbens reveal
GABA-mediated responses: implications for intracranial self-stimulation. Proc
Natl Acad Sci U S A 102:19150-19155.2005).
Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (Cannabinoids enhance
subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci
24:4393-4400.2004).
Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE,
Wightman RM (Phasic dopamine release evoked by abused substances requires
cannabinoid receptor activation. J Neurosci 27:791-795.2007).
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA,
Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper
CB, Yanagisawa M (Narcolepsy in orexin knockout mice: molecular genetics of
sleep regulation. Cell 98:437-451.1999).
Covey DP, Juliano SA, Garris PA (Amphetamine elicits opposing actions on readily
releasable and reserve pools for dopamine. PLoS One 8:e60763.2013).
Covey DP, Roitman MF, Garris PA (Illicit dopamine transients: reconciling actions of
abused drugs. Trends Neurosci In Press.2014).
Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, Kingsbury L, Arora S, Schwartz
JR, Niebler GE, Dinges DF (Modafinil for excessive sleepiness associated with
shift-work sleep disorder. N Engl J Med 353:476-486.2005).
Daberkow DP, Brown HD, Bunner KD, Kraniotis SA, Doellman MA, Ragozzino ME,
Garris PA, Roitman MF (Amphetamine paradoxically augments exocytotic
dopamine release and phasic dopamine signals. J Neurosci 33:452-463.2013).
Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, Chouvet G (Prominent burst firing
of dopaminergic neurons in the ventral tegmental area during paradoxical sleep.
Neuropsychopharmacology 32:1232-1241.2007).
Day JJ, Roitman MF, Wightman RM, Carelli RM (Associative learning mediates
dynamic shifts in dopamine signaling in the nucleus accumbens. Nat Neurosci
10:1020-1028.2007).
de Saint HZ, Orosco M, Rouch C, Blanc G, Nicolaidis S (Variations in extracellular
monoamines in the prefrontal cortex and medial hypothalamus after modafinil
administration: a microdialysis study in rats. Neuroreport 12:3533-3537.2001).
Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le MM, Piazza PV (Study of
the addictive potential of modafinil in naive and cocaine-experienced rats.
Psychopharmacology (Berl) 161:387-395.2002).

26

Di CG, Imperato A (Drugs abused by humans preferentially increase synaptic dopamine
concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad
Sci U S A 85:5274-5278.1988).
Edgar DM, Seidel WF (Modafinil induces wakefulness without intensifying motor
activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther
283:757-769.1997).
Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K (The
antinarcoleptic drug modafinil increases glutamate release in thalamic areas and
hippocampus. Neuroreport 8:2883-2887.1997a).
Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K (Modafinil: an
antinarcoleptic drug with a different neurochemical profile to d-amphetamine and
dopamine uptake blockers. Biol Psychiatry 42:1181-1183.1997b).
Garris PA, Kilpatrick M, Bunin MA, Michael D, Walker QD, Wightman RM
(Dissociation of dopamine release in the nucleus accumbens from intracranial
self-stimulation. Nature 398:67-69.1999).
Grace AA, Bunney BS (The control of firing pattern in nigral dopamine neurons: burst
firing. J Neurosci 4:2877-2890.1984a).
Grace AA, Bunney BS (The control of firing pattern in nigral dopamine neurons: single
spike firing. J Neurosci 4:2866-2876.1984b).
Harun R, Grassi CM, Munoz MJ, Torres GE, Wagner AK (Neurobiological model of
stimulated dopamine neurotransmission to interpret fast-scan cyclic voltammetry
data. Brain Res 1599:67-84.2015).
Heien ML, Johnson MA, Wightman RM (Resolving neurotransmitters detected by fastscan cyclic voltammetry. Anal Chem 76:5697-5704.2004).
Hermans A, Keithley RB, Kita JM, Sombers LA, Wightman RM (Dopamine detection
with fast-scan cyclic voltammetry used with analog background subtraction. Anal
Chem 80:4040-4048.2008).
Hyman SE, Malenka RC, Nestler EJ (Neural mechanisms of addiction: the role of
reward-related learning and memory. Annu Rev Neurosci 29:565-598.2006).
Ishizuka T, Murakami M, Yamatodani A (Involvement of central histaminergic systems
in modafinil-induced but not methylphenidate-induced increases in locomotor
activity in rats. Eur J Pharmacol 578:209-215.2008).
Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A (Modafinil increases histamine
release in the anterior hypothalamus of rats. Neurosci Lett 339:143-146.2003).
Keithley RB, Heien ML, Wightman RM (Multivariate concentration determination using
principal component regression with residual analysis. Trends Analyt Chem
28:1127-1136.2009).

27

Kelland MD, Chiodo LA, Freeman AS (Anesthetic influences on the basal activity and
pharmacological responsiveness of nigrostriatal dopamine neurons. Synapse
6:207-209.1990).
Koulchitsky S, De BB, Quertemont E, Charlier C, Seutin V (Differential effects of
cocaine on dopamine neuron firing in awake and anesthetized rats.
Neuropsychopharmacology 37:1559-1571.2012).
Kuczenski R, Segal DS (Locomotor effects of acute and repeated threshold doses of
amphetamine and methylphenidate: relative roles of dopamine and
norepinephrine. J Pharmacol Exp Ther 296:876-883.2001).
Kuczenski R, Segal DS, Aizenstein ML (Amphetamine, cocaine, and fencamfamine:
relationship between locomotor and stereotypy response profiles and caudate and
accumbens dopamine dynamics. J Neurosci 11:2703-2712.1991).
Kumar R (Approved and investigational uses of modafinil : an evidence-based review.
Drugs 68:1803-1839.2008).
Kume-Kick J, Rice ME (Dependence of dopamine calibration factors on media Ca2+ and
Mg2+ at carbon-fiber microelectrodes used with fast-scan cyclic voltammetry. J
Neurosci Methods 84:55-62.1998).
Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L,
Katz JL, Tanda G, Newman AH (R-modafinil (armodafinil): a unique dopamine
uptake inhibitor and potential medication for psychostimulant abuse. Biol
Psychiatry 72:405-413.2012).
Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ,
Bonab AA, Miller GM, Fischman AJ (Modafinil occupies dopamine and
norepinephrine transporters in vivo and modulates the transporters and trace
amine activity in vitro. J Pharmacol Exp Ther 319:561-569.2006).
Michael D, Travis ER, Wightman RM (Color images for fast-scan CV measurements in
biological systems. Anal Chem 70:586A-592A.1998).
Mignot E, Nishino S, Guilleminault C, Dement WC (Modafinil binds to the dopamine
uptake carrier site with low affinity. Sleep 17:436-437.1994).
Muller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ (Effects of
modafinil on non-verbal cognition, task enjoyment and creative thinking in
healthy volunteers. Neuropharmacology 64:490-495.2013).
Oleson EB, Talluri S, Childers SR, Smith JE, Roberts DC, Bonin KD, Budygin EA
(Dopamine uptake changes associated with cocaine self-administration.
Neuropsychopharmacology 34:1174-1184.2009).
Pace-Schott EF, Hobson JA (The neurobiology of sleep: genetics, cellular physiology and
subcortical networks. Nat Rev Neurosci 3:591-605.2002).

28

Pack AI, Black JE, Schwartz JR, Matheson JK (Modafinil as adjunct therapy for daytime
sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 164:16751681.2001).
Park J, Aragona BJ, Kile BM, Carelli RM, Wightman RM (In vivo voltammetric
monitoring of catecholamine release in subterritories of the nucleus accumbens
shell. Neuroscience 169:132-142.2010).
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. New York:
Academic Press.
Phillips PE, Robinson DL, Stuber GD, Carelli RM, Wightman RM (Real-time
measurements of phasic changes in extracellular dopamine concentration in freely
moving rats by fast-scan cyclic voltammetry. Methods Mol Med 79:443464.2003a).
Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM (Subsecond dopamine
release promotes cocaine seeking. Nature 422:614-618.2003b).
Ramsson ES, Howard CD, Covey DP, Garris PA (High doses of amphetamine augment,
rather than disrupt, exocytotic dopamine release in the dorsal and ventral striatum
of the anesthetized rat. J Neurochem 119:1162-1172.2011).
Repantis D, Schlattmann P, Laisney O, Heuser I (Modafinil and methylphenidate for
neuroenhancement in healthy individuals: A systematic review. Pharmacol Res
62:187-206.2010).
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (Cocaine receptors on dopamine
transporters are related to self- administration of cocaine. Science 237:12191223.1987).
Roberts JG, Lugo-Morales LZ, Loziuk PL, Sombers LA (Real-time chemical
measurements of dopamine release in the brain. Methods Mol Biol 964:275294.2013).
Robinson DL, Phillips PE, Budygin EA, Trafton BJ, Garris PA, Wightman RM (Subsecond changes in accumbal dopamine during sexual behavior in male rats.
Neuroreport 12:2549-2552.2001).
Robinson DL, Wightman RM (2007) Rapid dopamine release in freely moving rats. In:
Electrochemical Methods for Neuroscience (Michael AC, Borland LM, eds), pp
17-34 Boca Raton: CRC Press.
Schmitt KC, Rothman RB, Reith ME (Nonclassical pharmacology of the dopamine
transporter: atypical inhibitors, allosteric modulators, and partial substrates. J
Pharmacol Exp Ther 346:2-10.2013).
Schultz W, Dayan P, Montague PR (A neural substrate of prediction and reward. Science
275:1593-1599.1997).

29

Shearer J, Darke S, Rodgers C, Slade T, van B, I, Lewis J, Brady D, McKetin R, Mattick
RP, Wodak A (A double-blind, placebo-controlled trial of modafinil (200 mg/day)
for methamphetamine dependence. Addiction 104:224-233.2009).
Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS (Dual effects of D-amphetamine on
dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci
20:3504-3511.2000).
Shi WX, Pun CL, Zhou Y (Psychostimulants induce low-frequency oscillations in the
firing activity of dopamine neurons. Neuropsychopharmacology 29:21602167.2004).
Sombers LA, Beyene M, Carelli RM, Wightman RM (Synaptic overflow of dopamine in
the nucleus accumbens arises from neuronal activity in the ventral tegmental area.
J Neurosci 29:1735-1742.2009).
Stuber GD, Roitman MF, Phillips PE, Carelli RM, Wightman RM (Rapid dopamine
signaling in the nucleus accumbens during contingent and noncontingent cocaine
administration. Neuropsychopharmacology 30:853-863.2005).
Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J
(Modafinil film-coated tablets in children and adolescents with attentiondeficit/hyperactivity disorder: results of a randomized, double-blind, placebocontrolled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry
67:137-147.2006).
Tanganelli S, Fuxe K, Ferraro L, Janson AM, Bianchi C (Inhibitory effects of the
psychoactive drug modafinil on gamma-aminobutyric acid outflow from the
cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol
345:461-465.1992).
Tella SR, Ladenheim B, Cadet JL (Differential regulation of dopamine transporter after
chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther
281:508-513.1997).
Tripp G, Wickens JR (Research review: dopamine transfer deficit: a neurobiological
theory of altered reinforcement mechanisms in ADHD. J Child Psychol
Psychiatry.2008).
Vander Weele CM, Porter-Stransky KA, Mabrouk OS, Lovic V, Singer BF, Kennedy RT,
Aragona BJ (Rapid dopamine transmission within the nucleus accumbens:
dramatic difference between morphine and oxycodone delivery. Eur J Neurosci
40:3041-3054.2014).
Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P, Augustine GJ,
Wightman RM (Cocaine increases dopamine release by mobilization of a
synapsin-dependent reserve pool. J Neurosci 26:3206-3209.2006).
Venton BJ, Wightman RM (Pharmacologically induced, subsecond dopamine transients
in the caudate-putamen of the anesthetized rat. Synapse 61:37-39.2007).
30

Walters SH, Taylor IM, Shu Z, Michael AC (A novel restricted diffusion model of
evoked dopamine. ACS Chem Neurosci 5:776-783.2014).
Ward CP, Harsh JR, York KM, Stewart KL, McCoy JG (Modafinil facilitates
performance on a delayed nonmatching to position swim task in rats. Pharmacol
Biochem Behav 78:735-741.2004).
Watson CJ, Venton BJ, Kennedy RT (In vivo measurements of neurotransmitters by
microdialysis sampling. Anal Chem 78:1391-1399.2006).
Wightman RM, Amatore C, Engstrom RC, Hale PD, Kristensen EW, Kuhr WG, May LJ
(Real-time characterization of dopamine overflow and uptake in the rat striatum.
Neuroscience 25:513-523.1988).
Wightman RM, Kuhr WG, Ewing AG (Voltammetric detection of dopamine release in
the rat corpus striatum. Ann N Y Acad Sci 473:92-105.1986).
Willuhn I, Burgeno LM, Groblewski PA, Phillips PE (Excessive cocaine use results from
decreased phasic dopamine signaling in the striatum. Nat Neurosci 17:704709.2014).
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF (Treatment of narcolepsy and
other hypersomnias of central origin. Sleep 30:1712-1727.2007).
Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (Dopaminergic role in
stimulant-induced wakefulness. J Neurosci 21:1787-1794.2001).
Wu Q, Reith ME, Kuhar MJ, Carroll FI, Garris PA (Preferential increases in nucleus
accumbens dopamine after systemic cocaine administration are caused by unique
characteristics of dopamine neurotransmission. J Neurosci 21:6338-6347.2001a).
Wu Q, Reith ME, Wightman RM, Kawagoe KT, Garris PA (Determination of release and
uptake parameters from electrically evoked dopamine dynamics measured by
real-time voltammetry. J Neurosci Methods 112:119-133.2001b).
Yorgason JT, Jones SR, Espana RA (Low and high affinity dopamine transporter
inhibitors block dopamine uptake within 5 sec of intravenous injection.
Neuroscience 182:125-132.2011).
Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE,
Baumann MH (Evidence for the involvement of dopamine transporters in
behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329:738746.2009).

31

Figure 1. Schematic of modafinil effects on dopamine signaling. MOD generated DA
transients in DA neuron terminal fields by activating burst firing at the level of the cell
body. Furthermore, MOD enhanced phasic DA signaling at presynaptic levels by
inhibiting DA uptake and enhancing DA release (top). MOD effects on phasic DA
signaling results in increased frequency and enhanced amplitude of DA transients
(bottom).
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Figure 2. Representative effects of modafinil on electrically evoked phasic-like
dopamine signals in the dorsal and ventral striatum. MOD (100 mg/kg i.p.) effects on
electrically evoked phasic-like DA signals in the (A) dorsal and (B) ventral striatum
measured by FSCV. (Top) Evoked DA signals elicited by electrical stimulation
(demarcated by black line at time 0 s) pre-drug (left) and 60 minutes post-MOD (right)
administration. INSET. Individual background subtracted cyclic voltammogram taken
from the peak signal amplitude (white vertical line) identifies the analyte as DA.
(Bottom) Pseudo-color plot serially displaying all background-subtracted cyclic
voltammograms (x-axis: time; y-axis: applied potential; z-axis: current). White horizontal
line identifies the DA peak oxidation potential where the evoked DA trace was collected.
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Figure 3. Average time courses of modafinil effects on [DA]max in the dorsal and ventral
striatum. MOD elicits time- and dose-dependent effects on the maximal concentration of
the electrically evoked phasic-like DA signal amplitude ([DA]max) in the dorsal (A) and
ventral (B) striatum. Data are expressed as a percent of pre-drug and are the mean±SEM.
Arrow demarcates MOD administration at time 0 min. Data were analyzed for
significance using three-way repeated measures ANOVA (n = 4-7).
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Figure 4. Qualitative analysis of dopamine uptake on electrically evoked phasic-like
dopamine signals. Representative time- and dose-dependent effects of MOD on
extracellular clearance of electrically evoked DA in the (A) dorsal and (B) ventral
striatum. FSCV traces of electrically evoked DA signals (stimulus demarcated by short
black line) are shown for 100 mg/kg MOD (left) and 300 mg/kg MOD (right) at select
time points. INSET. Pre- and post-drug clearance curves are overlaid beginning at the
same dopamine concentration and illustrate DA uptake inhibition.
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Figure 5. Effects of modafinil on [DA]max, dopamine release, and dopamine uptake.
Increases in the maximal concentration of the electrically evoked phasic-like DA signal
([DA]max) (left) are associated with an increase in DA release (middle) and a decrease in
DA uptake or k (right) in the dorsal (A) and ventral (B) striatum. Data are expressed as a
percentage of pre-drug values and are the mean±SEM. Data were analyzed for
significance using three-way repeated measures ANOVA (n = 4-7).
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Figure 6. Path analysis of dose-dependent effects of modafinil on [DA]max. Path analysis
model demonstrating the direct relationships between dose, DA release, DA uptake and
[DA]max. Values given above each arrow are path coefficients describing each direct
effect.
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Figure 7. Effects of modafinil on non-electrically evoked dopamine signals. MOD
effects on changes in basal DA levels in the dorsal and ventral striatum. (A) The red line
displays PCR resolved DA from the black FSCV trace (taken at the white horizontal line)
for pre-drug and 60 minutes post-drug (300 mg/kg i.p.). A pseudo-color plot beneath
displays all background subtracted cyclic voltammograms. INSET. Representative
voltammogram (blue) collected at 285 s (white vertical line) overlaid with a
voltammogram taken at peak electrically evoked signal (black). (B) PCR reveals no
significant effect of MOD on baseline DA levels in the dorsal (top) and ventral (bottom)
striatum. Data were analyzed for significance using three-way repeated measures
ANOVA (n = 4). (C) Verification of PCR selectivity for the DA component in FSCV
recordings. There was a strong correlation between [DA]max measured with FSCV
([DA]FSCV) and PCR ([DA]PCR) in both the dorsal (left) and ventral (right) striatum.
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Figure 8. Modafinil effects on dopamine transients. DA transients are elicited in both the
dorsal and ventral striatum by co-administration of MOD (30 mg/kg, i.p.) and raclopride
(2 mg/kg, i.p.). (A) Representative recording of DA transients in the dorsal (left) and
ventral (right) striatum. A pseudo-color plot underneath serially displays all backgroundsubtracted cyclic voltammograms. Transients (denoted by red asterisks) are displayed in
the FSCV current trace collected at the peak oxidative potential of DA (white horizontal
line). INSET. Normalized background subtracted cyclic voltammograms taken from the
electrically-evoked response (black line) and a DA transient (red line) collected at the
white vertical line in the pseudo-color plot. (B) Average transient frequency per 5 minute
epoch for pre- and post-drug administration expressed as mean±SEM. Data were
analyzed for significance using two repeated measures ANOVA (dorsal, n = 6; ventral n
= 5).
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CHAPTER II
ATOMOXETINE ALTERS PHASIC DOPAMINE SIGNALING IN THE NUCLEUS
ACCUMBENS OF THE RAT: A PRELIMINARY STUDY
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ABSTRACT
Atomoxetine (ATX), brand name Strattera®, has been approved for the treatment
of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.
By selectively targeting norepinephrine neurons, its underlying mechanism differs from
that of the primary drugs used to treat ADHD, Adderall® and Ritalin®. Altered
reinforcement learning is a symptom of ADHD that is proposed to be mediated by
alterations in phasic dopamine (DA) signaling. During this mode of neural
communication, burst firing of DA neurons generate rapid changes in extracellular DA
concentrations in DA terminal fields termed DA transients. Although Adderall® and
Ritalin® are thought to act on phasic DA signaling, whether ATX shares this
pharmacologic property is not known. ATX’s effect on phasic DA signaling was
investigated with fast-scan cyclic voltammetry at a carbon fiber microelectrode targeting
the nucleus accumbens core. Three types of phasic DA signals were assessed: (1)
electrically evoked phasic-like DA signals, which resemble naturally occurring DA
transients; (2) spontaneously occurring DA transients, which are not ostensibly linked to
external stimuli; (3) DA transients elicited by unexpected food delivery, which is
considered a primary reward. Additionally, effects of ATX on the presynaptic
mechanisms of DA release and DA uptake, determined from the electrically evoked
signals, and ATX effects on food-pellet consumption were also assessed. Our preliminary
results suggest that ATX reduces electrically evoked phasic-like DA signals, food-pellet
consumption, and Food-evoked DA transients. Taken together, we propose that alteration
of phasic DA signaling may contribute to the mechanism of ATX action.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a debilitating neurodevelopmental
disorder, which affects approximately 6.5% of the world population (Polanczyk et al.,
2014). Its two cardinal symptoms, inattention and hyperactivity-impulsivity, ultimately
lead to poor success in academic and vocational pursuits (American Psychiatric
Association, 2013). Current therapeutic medications for treating ADHD include two
major classes of drugs: stimulants, amphetamine (AMPH; Adderall®) and
methylphenidate (MPH; Ritalin®), and the non-stimulant, atomoxetine (ATX;
Strattera®). As compared to the commonly prescribed stimulant therapeutics, ATX
possesses limited abuse potential (Tidey and Bergman, 1998; Jasinski et al., 2008), lacks
locomotor activation (Tzavara et al., 2006), and is efficacious in treating comorbid
conditions associated with ADHD, including depression and anxiety (Kratochvil et al.,
2005). However, stimulant therapeutics provide immediate onset of action as opposed to
ATX, which can take 3-4 weeks before achieving optimal therapeutic efficacy (Newcorn
et al., 2008). ATX’s mechanism of therapeutic efficacy remains incompletely understood,
but because of its efficacy for the treatment of ADHD with comorbid depression and
anxiety, along with its limited negative side-effects such as limited abuse potential, an
understanding of its mechanism is critical for future drug development.
ADHD patients exhibit deficits in executive function, including planning,
working memory, attention, and inhibition of inappropriate behaviors (American
Psychiatric Association, 2013). Executive function is associated with the prefrontal
cortex (PFC) (Alvarez and Emory, 2006), and ADHD patients are found to have altered
PFC anatomy and function (Rubia et al., 2005; Booth et al., 2005). In addition, ADHD
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patients exhibit associative learning deficits, including atypical responses to
reinforcement whereby patients choose small, instantaneous rewards rather than larger,
delayed rewards (Sonuga-Barke, 2003; Antrop et al., 2006). Associative learning is
linked to striatal function (Schultz, 1997; Day et al., 2007), and ADHD patients also
exhibit anatomic and functional alterations in this region (Scheres et al., 2007).
Altogether, symptoms in ADHD patients appear to be linked to abnormalities in both the
PFC and striatum and befittingly, conceptual models of ADHD focus on neural
alterations in these regions and their associated behaviors.
Current medications are thought to remediate symptoms of ADHD by
ameliorating neurochemical alterations in the PFC. Studies in rats show that AMPH,
MPH, and ATX enhance dopamine (DA) and norepinephrine (NE) levels in the PFC
(Kuczenski and Segal, 2001; Bymaster et al., 2002; Kuczenski and Segal, 2002; Berridge
and Stalnaker, 2002) and ameliorate symptoms of ADHD in humans (James et al., 2001;
Correia Filho et al., 2005; Ince et al., 2015). These findings have contributed to the
development of the inverted-U model of ADHD (Fig. 9). This model proposes that in the
PFC optimal function is dependent on optimal catecholamine release, and either too low
or too high levels of catecholamine release results in decreased PFC function (Arnsten
and Pliszka, 2011). Furthermore, ADHD patients are suggested to have lower levels of
catecholamine release, resulting in reduced PFC function and consequently, symptoms of
ADHD. Medications for ADHD are thought to enhance levels of catecholamine release to
more optimal levels, thereby enhancing PFC function and remediating symptoms of
ADHD.
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The inverted-U model of ADHD addresses many of the executive functions
altered in ADHD patients, but does not address alterations of associative learning. Thus,
alternative models of ADHD have emerged that focus on alterations in associative
learning (e.g., reinforcement learning) in the striatum. In particular, the dopamine transfer
deficit (DTD) theory (Fig. 10) proposes that phasic DA signaling in DA neurons
projecting from the midbrain to the striatum is altered in ADHD patients, which results in
reinforcement learning deficits (Tripp and Wickens, 2008). Phasic DA signaling is
critical for associative learning (Schultz et al., 1997) and is activated by primary rewards
(e.g., food) (Brown et al., 2011a) and reward-predictive cues (Day et al., 2007). During
normal reinforcement learning, phasic DA signaling is initially activated during reward
delivery. During acquisition of learning, phasic DA signals begin to be activated during
presentation of both the reward-predictive cue and the reward. Finally, later in learning,
phasic DA signaling is exclusively activated during presentation of reward-predicting
cues rather than reward delivery. The DTD theory hypothesizes that in ADHD patients,
the transfer of phasic DA signaling to the cue is incomplete, resulting in reinforcement
learning deficits. Furthermore, the theory proposes that ADHD medications ameliorate
alterations in reinforcement learning by enhancing the magnitude of phasic DA signaling
in the striatum elicited by the cue. However, this hypothesis has not yet been directly
investigated to our knowledge.
Indeed it has been shown that drugs such as AMPH activate phasic DA signaling
and this activation occurs through effects at the presynaptic level in the striatum (Avelar
et al., 2013) as well as via afferent activation of DA neurons in the midbrain (Darracq et
al., 1998; Shi et al., 2000; Shi et al., 2004). Phasic DA signaling is characterized by high
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frequency bursts of action potential firing (i.e., burst firing) (Grace and Bunney, 1984),
resulting in sub-second increases in DA concentration in DA terminal fields termed DA
transients. AMPH, a potent dopamine transporter (DAT)-inhibitor, also activates phasic
DA signaling at presynaptic terminals by inhibiting DA uptake and enhancing DA release
(Daberkow et al., 2013; Avelar et al., 2013). The resulting activation in phasic DA
signaling leads to enhanced frequency, amplitude and duration of DA transients. In
addition, AMPH is a potent norepinephrine transporter (NET)-inhibitor as well and
enhances NE levels in the PFC (Berridge and Stalnaker, 2002), which has been shown to
indirectly activate DA neuron burst firing via glutamate afferents to the midbrain (Fig.
11) (Darracq et al., 1998; Shi et al., 2000; Shi et al., 2004). Not unexpectedly then,
selective NET-inhibitors enhance burst firing of DA neurons (Shi et al., 2000; Shi et al.,
2004); however, their effects may also be mediated directly by activation of NE afferents
to the midbrain DA neurons (Fig. 3). Similarly, ATX, a selective NET-inhibitor may be
mediating its effects on phasic DA signaling via these mechanisms. However, due to the
absence of direct actions on DA terminals, its actions on the frequency, duration, and
amplitude of DA transients should be different than those of AMPH.
In the present study we sought it identify ATX’s effect on phasic DA signaling in
the freely behaving rat. Using fast-scan cyclic voltammetry (FSCV) at a carbon fiber
microelectrode (CFM) targeting the nucleus accumbens core (NAc), a region that is
activated during associative learning (Day et al., 2007), we examined the effects of ATX
on phasic DA signaling during unexpected food delivery (UFD). Specifically, we
investigated ATX effects on electrically evoked phasic-like DA transients, spontaneously
occurring DA transients, and DA transients associated with UFD. Furthermore, we also
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investigated ATX effects on the presynaptic mechanisms of DA release and uptake and
food-pellet consumption.
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Methods and Materials
Animals. Animal care was in accordance with NIH guidelines and approved by the
Institutional Animal Care and Use Committee (IACUC) at Illinois State University. Male
Sprague-Dawley rats (275-375 g) purchased from Harlan (Indianapolis, IN, USA) were
housed in a temperature controlled vivarium on a diurnal light cycle (12h light/dark).
Prior to training and during recovery, animals were provided food and water ad libitum.
During magazine training and testing, animals were food restricted to approximately 95%
original weight.
Surgery. Preparatory survival surgery was performed under isoflurane (0.5 to 2.5 %)
and aseptic conditions (Daberkow et al., 2013). Carprofen (5mg/kg s.c.) was administered
as an analgesic. Rats were immobilized in a stereotaxic apparatus and holes for reference,
stimulating, and recording electrodes and three screw holes were drilled. All stereotaxic
coordinates were made in relation to bregma according to (Paxinos and Watson, 1986).
The stimulating electrode was placed in the medial forebrain bundle (MFB; -4.6 AP, +1.3
ML, ~-7.5 DV). A recording electrode targeted the NAc (+1.3 AP, +1.5 ML, ~-6.5 DV).
The Ag/AgCl reference electrode was placed contralaterally in the superficial cortex.
During surgery, the stimulating electrode was optimized, after which dental cement was
used to fix the reference and stimulating electrode, and recording-electrode cannula
positioned over the NAc. Following surgery, heparin was applied once daily to prevent
blood clotting in the electrode cannula.
Electrochemistry. DA signals were recorded with FSCV at a CFM by applying a
triangular waveform (-0.4 to +1.3V and back) at a rate of 400V/s every 100 ms. CFMs
were fabricated in house by aspirating a single carbon fiber (HexTow AS4, HexCel
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Corp., Stamford, CT, USA) into a borosilicate capillary tube (1.2mm o.d.; Sutter
Instrument, Novato, CA, USA) and pulling to a taper using a micropipette puller
(Narishige, Tokyo, Japan). The carbon fiber was then cut to ~100 microns distal to the
glass-insulated seal. FSCV was performed by a Universal Electrochemistry Instrument
(UEI; Department of Chemistry Electronic Shop, University of North Carolina, Chapel
Hill, NC, USA) and commercially available software (ESA Bioscience, Chelmsford, MA,
USA). Current recorded at peak oxidative potential for DA (~+0.6 V) was converted to
DA concentration based on post-calibration of the CFM using flow-injection analysis
with a modified TRIS buffer (Kume-Kick and Rice, 1998; Wu et al., 2001; Phillips et al.,
2003). DA was identified from the background subtracted voltammogram (Michael et al.,
1998; Heien et al., 2004).
Measurements with Electrical Stimulation. Electrical stimulation was computer
generated and passed through an optical isolator and constant-current generator
(Neurolog NL800; Digitimer Limited, Letchworth Garden City, UK). Biphasic
stimulation pulses were applied to a twisted bipolar electrode (Plastics One, Roanoke,
VA, USA); tips were separated ~1 mm. Stimulus parameters were a current of ±125 μA
and a biphasic pulse duration of 4 ms (2 ms each phase), and trains were applied at a
frequency of 60 Hz for 0.4 s.
Unexpected Food Delivery. UFD was performed as previously described (Brown et
al., 2011b). In brief, prior to surgery, rats were food restricted and given two sessions
(one per day) to retrieve food-pellets in a standard operant chamber (Med Associates).
During this magazine training single food pellets were delivered at a variable inter-trial
interval (range 30-90 seconds; average 60 second inter-trial interval; 30 trials). After
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surgery, rats received one additional magazine training with the headstage attached. The
following day, a CFM was lowered and optimized for both food evoked and electrically
evoked DA signals. DA was recorded with FSCV. After optimization, electrically evoked
DA signals were collected pre-drug following 10 minutes of habituation followed by a
UFD paradigm, which has identical parameters as the magazine training sessions. After
UFD, rats were administered saline or ATX (1 or 10 mg/kg i.p.), followed by 10 minutes
of habituation and a final UFD paradigm. After the second UFD, electrically evoked
phasic-like DA signals were collected.
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Results
Atomoxetine Inhibits Food-Pellet Consumption. Our results suggest that all rats
administered ATX (10 mg/kg) became anorexic (data not shown). Animals were
considered anorexic if all food-pellets were not consumed during the final session of
UFD.
Atomoxetine Diminishes Electrically Evoked Phasic-Like Dopamine Signals.
Figure 12 shows average effects of ATX (n=4) on electrically evoked phasic-like DA
signals. Maximal signal amplitude is expressed as a ratio of DA elicited post-drug/predrug. Our results suggest that ATX diminished electrically evoked phasic-like DA
signals. Changes in the electrically evoked phasic-like DA signal amplitude are
potentially mediated by DA release and/or uptake (Wu et al., 2001); however, potential
presynaptic effects of ATX have yet to be investigated.
Atomoxetine Reduces Food-Evoked Dopamine Transients. Figure 13 shows
saline (A) and ATX (B) representative effects on food-evoked DA transients. Saline (A)
showed no effect on food-evoked DA transients (pre-drug, left; post-drug, right). The top
of each panel shows DA concentration collected as the current recorded at the peak
oxidative potential for DA and converted to concentration by post-calibration. Pseudocolor plots below showing sequential voltammograms and individual voltammograms
(inset) identify DA as the primary analyte elicited initially by UFD by its electrochemical
profile. ATX (B) in this representative example appears to entirely prevent the foodevoked DA transient. Average (n=4) effects of ATX on food-evoked DA transients (C).
Similar to the representative data, ATX strongly decreased the amplitude of food-evoked
DA transients expressed as a ratio of post-drug/pre-drug transients.
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Future Directions
Our preliminary results suggest that ATX alters phasic DA signaling; however, further
investigation of its effects are warranted. First, the surprising effect of ATX on
electrically evoked phasic-like DA signals will be investigated by assessing presynaptic
mechanisms of DA release and DA uptake. Additionally, the effects of ATX will be
examined on spontaneous DA transients by analyzing effects of ATX on transient
frequency, amplitude and duration. Lastly, a lower behaviorally relevant dose of ATX (1
mg/kg) will be investigated. As dose plays an important role in drug efficacy (Berridge
and Stalnaker, 2002), investigation of ATX at various doses is valuable in identifying
potentially different mechanisms of action.
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Figure 9. Inverted-U model of attention deficit hyperactivity disorder. Optimal
catecholamine release results in optimal PFC function. ADHD patients are thought to
exhibit low catecholamine release and concomitantly low PFC function. Therapeutic
drugs for ADHD enhance catecholamine release and thereby enhance PFC function in
ADHD patients.
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Figure 10. Reinforcement learning and dopamine function. Phasic DA signaling is
activated after rewards and cues predicting their rewards. Before reward-prediction
learning, phasic DA signals are activated by rewards and not to the presentation of the
cue. In early learning phasic DA signaling is activated by cue onset and reward delivery.
Finally, late in learning, phasic DA signaling transfers from the reward to the cue. In
ADHD patients, the DTD theory proposes that the transfer of phasic Da signaling from
the reward to the cue is incomplete resulting in altered reinforcement learning.
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Figure 11. Afferent input and midbrain dopamine neurons. Projections from the PFC and
LC terminate on midbrain DA neurons and alter DA signaling. NE cell bodies originate
in the LC and project to the PFC and to midbrain DA neurons, which originate in the
VTA and SN. In the PFC, glutamate axons project to midbrain DA neurons. In the
midbrain, DA axons project to both the striatum and PFC. Abbreviations: PFC, prefrontal
cortex; DS, dorsal striatum; SN, substantia nigra; VTA, ventral tegmental area; LC, locus
coeruleus.
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Figure 12. Atomoxetine decreases amplitude of electrically evoked phasic-like dopamine
signals. Traces show increased [DA] after electrical stimulation at 5 s. Color plots below
and voltammograms (inset) identify DA as primary analyte. Saline (A) shows slight
increase in electrically evoked phasic-like [DA] (A: right) compared to pre-drug (A: left).
ATX (B: right) shows decrease in electrically evoked [DA] compared to pre-drug (B:
left). Below (C) shows average electrically evoked phasic-like DA amplitude expressed
as a ratio of post-drug over pre-drug and are mean ± SEM. Saline: n = 2; ATX: n = 4.
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Figure 13. Atomoxetine decrease food-evoked dopamine transients. Representative
saline (A) and ATX (10 mg/kg) (B) effects on Food-evoked DA transients. Average color
plots of raw FSCV data illustrating the effect on unexpected food delivery before (left)
and of (right) saline (A) and ATX (B). (Top) DA transients elicited by unexpected food
delivery (left) and post-drug (right) taken at peak oxidation potential of DA (white
dashed line). INSET: individual voltammogram taken from peak signal amplitude
identifying the analyte as DA. Average effects of ATX and saline on Food-evoked DA
transients (C). Data are expressed as a ratio of post-drug over pre-drug and are mean ±
SEM. Saline: n = 3; ATX: n = 4. Saline: n = 3; ATX: n = 4.
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